AIM ImmunoTechAIM -12.18%33 PB Ratio is 1.21 as of Jun. 28, 2026, which is 12% below its 10-year median of 1.37. GuruFocus rates AIM with a GF Score™ of 33/100 and a GF Value™ of $2.69 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,232 Biotechnology companies, AIM ImmunoTech ranks better than 77.19% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-28), AIM ImmunoTech's share price is $0.3121. AIM ImmunoTech's Book Value per Share for the quarter that ended in Mar. 2026 was $0.26. Hence, AIM ImmunoTech's PB Ratio of today is 1.21.
The historical rank and industry rank for AIM ImmunoTech's PB Ratio or its related term are showing as below:
AIM'
s PB Ratio Range Over the Past 10 Years
Min: 0.18 Med: 1.37 Max: 7.39
Current: 1.21
During the past 13 years, AIM ImmunoTech's highest PB Ratio was 7.39. The lowest was 0.18. And the median was 1.37.
AIM's PB Ratio is ranked better than 77.19% of 1232
companies
in the Biotechnology industry
Industry Median: 2.815
vs AIM: 1.21
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of AIM ImmunoTech was 72.50% per year. The lowest was -63.90% per year. And the median was -14.30% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
AIM ImmunoTech PB Ratio Related Terms
AIM ImmunoTech PB Ratio Historical Data
* Premium members only.
The historical data trend for AIM ImmunoTech's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, AIM ImmunoTech's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AIM ImmunoTech PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's PB Ratio distribution charts can be found below:
* The bar in red indicates where AIM ImmunoTech's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
AIM ImmunoTech's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
AIM ImmunoTech (AIM) has a PB Ratio of 1.21 as of Jun. 28, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on AIM ImmunoTech and its competitors. This is 12% below median its historical median of 1.37. Over the past decade, AIM ImmunoTech's PB Ratio has ranged from 0.18 to 7.39. According to the industry distribution chart, AIM ImmunoTech ranks #281 out of 1232 companies in the Biotechnology industry, placing it in the top 22.8%.
Is AIM ImmunoTech's PB Ratio too high?
AIM ImmunoTech's current PB Ratio of 1.21 is 12% below median its 10-year median of 1.37. Over the past 10 years, this metric has ranged from a low of 0.18 to a high of 7.39. The Biotechnology industry median PB Ratio is 2.82. AIM ImmunoTech's value of 1.21 is 57% below this industry median. Based on the distribution chart, AIM ImmunoTech ranks #281 out of 1232 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, AIM ImmunoTech has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AIM ImmunoTech's PB Ratio compare to BGMS and FBLG?
According to the Biotechnology industry distribution chart, AIM ImmunoTech ranks #281 out of 1232 companies for PB Ratio. This places AIM ImmunoTech in the top 23% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.82. AIM ImmunoTech's value of 1.21 is 57% below this benchmark. Historically, AIM ImmunoTech's own PB Ratio has ranged from 0.18 to 7.39 over the past decade. While the company's 10-year median is 1.37 vs. the industry median of 2.82, AIM ImmunoTech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.82, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AIM ImmunoTech's current PB Ratio of 1.21 is 57% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on AIM ImmunoTech and its competitors. For the Biotechnology industry, the median PB Ratio is 2.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AIM ImmunoTech's current PB Ratio is 1.21, which is 12% below median its own 10-year median of 1.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AIM ImmunoTech stock overvalued right now?
Based on GuruFocus' analysis, AIM ImmunoTech (AIM) is currently considered Possible Value Trap. The stock's GF Value™ is $2.69, compared to a current price of $0.31 — trading 88.4% below its estimated fair value. The current PB Ratio is 1.21, which is 12% below median its 10-year median of 1.37 and 57% below the Biotechnology industry median of 2.82. AIM ImmunoTech's overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For AIM ImmunoTech (AIM), the current PB Ratio is 1.21 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AIM ImmunoTech (AIM) Overvalued in 2026?
Based on GuruFocus' analysis, AIM ImmunoTech stock appears to be undervalued.
The current stock price of $0.31 is trading 88.4% below its estimated GF Value™ of $2.69.
GuruFocus considers AIM ImmunoTech to be Possible Value Trap.
Key valuation signals for AIM:
PB Ratio: 1.21 (12% below median its 10-year median of 1.37)
GF Value™: $2.69 vs. price of $0.31 (88.4% below fair value)
Industry Position: 57% below the Biotechnology median (#281 of 1232)
No single metric tells the full story. See the AIM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
33GF Score
Get the complete analysis for AIM
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AIM has been successfully added to your 
